Page 42 - Product Testing News Today

Press release content from Business Wire. The AP news staff was not involved in its creation. Canada Purchases Additional 4 Million Doses of Moderna’s COVID-19 Vaccine February 12, 2021 GMT CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 12, 2021-- Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Canadian Government has increased its confirmed order commitment by 4 million doses of the COVID-19 Vaccine Moderna bri...

For more than two months, a 73-year-old cancer patient fought COVID-19 at the University of Pittsburgh Medical Center.

MINNEAPOLIS — Minnesota health officials urged this week that people wear masks — and wear them properly — as the state reported an additional 964 new infections on Saturday.

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Athenex Announces New England Journal of Medicine Publication of Phase III Data on the Efficacy ... Athenex, Inc.February 11, 2021 GMT The New England Journal of Medicine published the Phase III trial results on Klisyri®, an anti-proliferative agent that inhibits tubulin polymerization and Src kinase signaling, for the topical treatment of actinic keratosis (AK) of the face or scalp Klisyri®, develo...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. AC Immune’s Alzheimer’s Vaccine Generates Potent Anti-pTau Antibody Response in a Phase 1b/2a Study AC Immune SAFebruary 11, 2021 GMT Interim results of ACI-35.030 vaccination show high titers of antigen-specific antibodies at potentially therapeutic levels in 100% of older patients with early Alzheimer’s disease ACI-35.030 was safe and well tolerated with no safety concerns observed. Results su...

Press release content from Business Wire. The AP news staff was not involved in its creation. Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity February 11, 2021 GMT CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 11, 2021-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2020 and reviewed re...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. BioXcel Therapeutics to Host Virtual Key Opinion Leader Event to Highlight BXCL501 as a ... BioXcel TherapeuticsFebruary 12, 2021 GMT NEW HAVEN, Conn., Feb. 12, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscienc...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Medicenna Reports Third Quarter Fiscal 2021 Financial Results and Operational Highlights Medicenna Therapeutics Corp.February 12, 2021 GMT TORONTO and HOUSTON, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “Company”) (NASDAQ: MDNA, TSX: MDNA), a clinical stage immuno-oncology company, today announced its financial results and operational highlights for the quar...

Press release content from Business Wire. The AP news staff was not involved in its creation. Poxel Reports Financial Update for Cash and Revenue for the Full Year 2020 and Provides Corporate Update February 12, 2021 GMT LYON, France--(BUSINESS WIRE)--Feb 12, 2021-- POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Applied Therapeutics, Inc. Announces Pricing of Public Offering of 3,000,000 Shares of Common Stock Applied TherapeuticsFebruary 11, 2021 GMT NEW YORK, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet ...